ARS Pharmaceuticals
SPRY
208 hedge funds and large institutions have $726M invested in ARS Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 72 increasing their positions, 56 reducing their positions, and 31 closing their positions.
300% more call options, than puts
Call options by funds: $2.53M | Put options by funds: $633K
29% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 56
23% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 31
2% more funds holding
Funds holding: 203 → 208 (+5)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3.53% less ownership
Funds ownership: 94.77% → 91.24% (-3.5%)
22% less capital inflows, than outflows
Capital inflows: $94.8M | Capital outflows: $121M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$23.7M |
| 2 |
TCM
Tyro Capital Management
Miami,
Florida
|
+$12.8M |
| 3 |
Boothbay Fund Management
New York
|
+$11.6M |
| 4 |
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$5.78M |
| 5 |
Rubric Capital Management (New York)
New York
|
+$4.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$30.8M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$26.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10.7M |
| 4 |
BAMCO Inc
New York
|
-$10.2M |
| 5 |
ADAR1 Capital Management
Austin,
Texas
|
-$6.54M |
SPRY Hedge Fund Activity: Q2 2026 in Review
208 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2026, worth a combined $726M — down 4.2% from $758M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new SPRY positions and 31 closed out — a net gain of 7 holders — while 72 added to existing stakes and 56 trimmed.
The largest buyer was Capital World Investors, opening a new position worth an estimated $23.7M. The largest seller was Millennium Management, cutting an estimated $30.8M.
- 208 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2026, up from 203 in Q1 2026.
- Funds reported $726M of ARS Pharmaceuticals stock for Q2 2026, down 4.2% quarter-over-quarter.
- 38 funds opened new ARS Pharmaceuticals positions in Q2 2026 and 31 closed out, a net change of +7 holders.
- The largest ARS Pharmaceuticals buyer in Q2 2026 was Capital World Investors, an estimated $23.7M added.
- The largest ARS Pharmaceuticals seller in Q2 2026 was Millennium Management, an estimated $30.8M sold.
Based on aggregated 13F filings for Q2 2026.